See more : Shenzhen Tellus Holding Co., Ltd. (000025.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Immuneering Corporation (IMRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immuneering Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Beijing Teamsun Technology Co.,Ltd. (600410.SS) Income Statement Analysis – Financial Results
- HealthCare Global Enterprises Limited (HCG.NS) Income Statement Analysis – Financial Results
- Vodafone Group Public Limited Company (VODI.DE) Income Statement Analysis – Financial Results
- STMicroelectronics N.V. (STMEF) Income Statement Analysis – Financial Results
- Impala Platinum Holdings Limited (IMPUF) Income Statement Analysis – Financial Results
Immuneering Corporation (IMRX)
About Immuneering Corporation
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 316.95K | 2.08M | 2.31M | 1.92M |
| Cost of Revenue | 764.14K | 158.12K | 1.15M | 1.28M | 1.22M |
| Gross Profit | -764.14K | 158.83K | 926.89K | 1.03M | 696.74K |
| Gross Profit Ratio | 0.00% | 50.11% | 44.56% | 44.61% | 36.29% |
| Research & Development | 41.40M | 36.27M | 26.54M | 15.00M | 4.28M |
| General & Administrative | 16.76M | 15.61M | 8.27M | 3.11M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.76M | 15.61M | 8.27M | 3.11M | 2.71M |
| Other Expenses | 0.00 | 30.05K | -127.06K | 0.00 | 0.00 |
| Operating Expenses | 58.41M | 51.90M | 34.81M | 18.11M | 6.99M |
| Cost & Expenses | 58.41M | 52.06M | 35.97M | 19.39M | 8.21M |
| Interest Income | 3.61M | 1.01M | 169.90K | 42.66K | 57.66K |
| Interest Expense | 0.00 | 1.01M | 0.00 | 0.00 | 351.30K |
| Depreciation & Amortization | 352.08K | 796.79K | 159.07K | 79.31K | 18.08K |
| EBITDA | -58.06M | -51.47M | -33.68M | -17.00M | -7.34M |
| EBITDA Ratio | 0.00% | -16,316.29% | -1,629.17% | -733.74% | -382.35% |
| Operating Income | -58.41M | -51.74M | -33.89M | -17.08M | -6.29M |
| Operating Income Ratio | 0.00% | -16,325.77% | -1,629.17% | -739.01% | -327.71% |
| Total Other Income/Expenses | 4.94M | 1.23M | 42.84K | 42.66K | -1.42M |
| Income Before Tax | -53.47M | -50.51M | -33.84M | -17.04M | -7.71M |
| Income Before Tax Ratio | 0.00% | -15,937.29% | -1,627.11% | -737.17% | -401.59% |
| Income Tax Expense | 0.00 | -1.23M | -307.49K | -84.34K | 351.30K |
| Net Income | -53.47M | -49.28M | -33.54M | -17.04M | -8.06M |
| Net Income Ratio | 0.00% | -15,548.66% | -1,612.33% | -737.17% | -419.89% |
| EPS | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| EPS Diluted | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| Weighted Avg Shares Out | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
| Weighted Avg Shares Out (Dil) | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates
Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
Source: https://incomestatements.info
Category: Stock Reports